Group 1: Company Overview - Hangzhou Lianchuan Biotechnology Co., Ltd. (Lianchuan Bio) has submitted an IPO application to the Beijing Stock Exchange, aiming to raise 300 million yuan, significantly reduced from the previous 608 million yuan planned for the Sci-Tech Innovation Board [1][3] - Lianchuan Bio focuses on the field of genetic technology, providing advanced research services and solutions based on high-throughput sequencing and bioinformatics technology [3][4] - The company has developed innovative gene detection medical devices, integrating basic research with clinical applications [3] Group 2: Financial Performance - As of December 31, 2024, Lianchuan Bio's total assets are projected to be approximately 771.54 million yuan, with total equity of about 536.42 million yuan [5] - The company reported a net profit of approximately 60.06 million yuan for the year ending December 31, 2024, with a gross profit margin of 48.73% [5] - The weighted average return on equity is expected to be 11.87% for 2024, with basic earnings per share projected at 1.29 yuan [5] Group 3: Use of Proceeds - The funds raised from the IPO will be allocated to three main projects: expansion and upgrade of the genetic technology product and service platform (20 million yuan), research and development of molecular diagnostic reagents (5 million yuan), and supplementing working capital (5 million yuan) [6] Group 4: Company Overview (Jianxin Superconductor) - Ningbo Jianxin Superconductor Technology Co., Ltd. specializes in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets and gradient coils [8] - The company is one of the earliest manufacturers in China to produce high-field superconducting magnets at scale, breaking the long-standing monopoly of foreign companies [8][9] - Jianxin Superconductor aims to raise funds through an IPO, with a target of issuing up to 41.92 million shares [9] Group 5: Financial Performance (Jianxin Superconductor) - For the year ending December 31, 2024, Jianxin Superconductor's total assets are projected to be approximately 671.28 million yuan, with a net profit of about 55.78 million yuan [10] - The company has a projected gross profit margin of 12.28% and basic earnings per share of 0.44 yuan for 2024 [10] Group 6: Use of Proceeds (Jianxin Superconductor) - The IPO proceeds will be used for several projects, including the production of 600 sets of non-liquid helium superconducting magnets (27.5 million yuan), upgrading the production of high-field medical superconducting magnets (26 million yuan), and research on new superconducting magnets (24 million yuan) [11]